Wobble Welcomes Industry Pioneer Dr. Dietrich Stephan as Chairman
Company - People | May 06, 2025 | EOS Investment Management Limited (Eos Advisory)
Wobble Genomics, a leading biotechnology firm recognized for its ultra-sensitive cell-free RNA (cfRNA) liquid biopsy diagnostic platform, has appointed Dr. Dietrich Stephan as Chairman of the Board. With extensive experience in biotechnology and genomics, Dr. Stephan's contributions include founding the first direct-to-consumer genomics company and advising major oncology ventures. Known for his work in molecular diagnostics and genome interpretation, Dr. Stephan's role is expected to bolster Wobble's mission to improve cancer treatment through innovation in diagnosis and therapy selection. His appointment complements Wobble's robust advisory panel, enhancing the company's potential to influence cancer treatment trajectories. Wobble Genomics is currently conducting studies in collaboration with the NHS in the UK to better understand and treat cancer.
Sectors
- Biotechnology
- Healthcare
Geography
- United Kingdom – Wobble Genomics is conducting clinical studies in partnership with the NHS, based in the UK.
- United States – Dr. Dietrich Stephan, the newly appointed Chairman, brings experience and networks from the US biotechnology sector, where significant developments in liquid biopsy have taken place.
Industry
- Biotechnology – The article focuses on Wobble Genomics, a biotechnology company specializing in liquid biopsy diagnostics, a key aspect of the biotech industry.
- Healthcare – Wobble Genomics operates in the healthcare sector, working on cancer diagnosis and treatment tools, essential components of modern patient care.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Wobble Genomics | Target Company | Company | A biotechnology company specializing in cfRNA liquid biopsy diagnostics for cancer. |
| Dr. Dietrich Stephan | Chairman | Person | An expert in genomics and biotechnology, appointed as Chairman of Wobble Genomics. |
| Dr. Richard Kuo | CEO and Founder | Person | Founder of Wobble Genomics, leading the company's mission in cancer diagnostics. |
| EOS Investment Management Limited (Eos Advisory) | Private Equity Firm | Company | Investment firm backing Wobble Genomics, facilitating its growth and development. |
| Dr. Richard Hockett | Chief Medical Officer | Person | Chief Medical Officer at Wobble Genomics, with a background in genomics from Eli Lilly and Affymetrix. |
| Dr. Han-Yu Chuang | Chief Technology Officer | Person | CTO at Wobble Genomics, previously held a leadership role at Guardant Health. |